| Drug General Information |
| Drug ID |
D0YK9D
|
| Former ID |
DIB019123
|
| Drug Name |
CHIR-99021
|
| Synonyms |
CHIR99021; CHIR 99021; CT-99021; CT99021
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C22H18Cl2N8
|
| InChI |
InChI=1S/C22H18Cl2N8/c1-13-10-29-21(31-13)17-12-30-22(32-20(17)16-4-3-15(23)8-18(16)24)27-7-6-26-19-5-2-14(9-25)11-28-19/h2-5,8,10-12H,6-7H2,1H3,(H,26,28)(H,29,31)(H,27,30,32)
|
| InChIKey |
AQGNHMOJWBZFQQ-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
14931758, 46052726, 77619611, 84982162, 90306847, 99222801, 99437061, 103566476, 103905640, 123105098, 124757128, 125163932, 125329941, 125333824, 126731259, 127443675, 131480740, 134216516, 135697745, 135727435, 136157396, 136367374, 136367993, 136920307, 137275880, 142261085, 144115822, 152043829, 152186750, 152258107, 152344405, 160646946, 162011409, 162037525, 162202606, 162211052, 162823708, 163685877, 163726080, 163780442, 163907957, 164042070, 164150165, 172087016, 172131585, 172649829, 174007034, 174528565, 180060723, 186006539
|
| Target and Pathway |
| Target(s) |
Cell division control protein 2 homolog |
Target Info |
Inhibitor |
[2]
|
|---|
| Glycogen synthase kinase-3 beta |
Target Info |
Inhibitor |
[2]
|
| mRNA of human glycogen synthase kinase 3 alpha |
Target Info |
Inhibitor |
[2]
|
| Mitogen-activated protein kinase 1 |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
Cell cycle
|
|
Oocyte meiosis
|
|
p53 signaling pathway
|
|
Gap junction
|
|
Progesterone-mediated oocyte maturation
|
|
Herpes simplex infection
|
|
Epstein-Barr virus infection
|
|
Viral carcinogenesishsa04012:ErbB signaling pathway
|
|
Chemokine signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Wnt signaling pathway
|
|
Hedgehog signaling pathway
|
|
Axon guidance
|
|
Hippo signaling pathway
|
|
Focal adhesion
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
T cell receptor signaling pathway
|
|
B cell receptor signaling pathway
|
|
Neurotrophin signaling pathway
|
|
Dopaminergic synapse
|
|
Insulin signaling pathway
|
|
Melanogenesis
|
|
Prolactin signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Alzheimer's disease
|
|
Hepatitis C
|
|
Measles
|
|
Influenza A
|
|
HTLV-I infection
|
|
Pathways in cancer
|
|
Colorectal cancer
|
|
Endometrial cancer
|
|
Prostate cancer
|
|
Basal cell carcinomahsa04062:Chemokine signaling pathway
|
|
Non-alcoholic fatty liver disease (NAFLD)hsa04010:MAPK signaling pathway
|
|
ErbB signaling pathway
|
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
cAMP signaling pathway
|
|
HIF-1 signaling pathway
|
|
FoxO signaling pathway
|
|
Sphingolipid signaling pathway
|
|
mTOR signaling pathway
|
|
Adrenergic signaling in cardiomyocytes
|
|
Vascular smooth muscle contraction
|
|
Dorso-ventral axis formation
|
|
TGF-beta signaling pathway
|
|
VEGF signaling pathway
|
|
Osteoclast differentiation
|
|
Adherens junction
|
|
Platelet activation
|
|
Toll-like receptor signaling pathway
|
|
NOD-like receptor signaling pathway
|
|
Natural killer cell mediated cytotoxicity
|
|
Fc epsilon RI signaling pathway
|
|
Fc gamma R-mediated phagocytosis
|
|
TNF signaling pathway
|
|
Circadian entrainment
|
|
Long-term potentiation
|
|
Retrograde endocannabinoid signaling
|
|
Glutamatergic synapse
|
|
Cholinergic synapse
|
|
Serotonergic synapse
|
|
Long-term depression
|
|
Regulation of actin cytoskeleton
|
|
GnRH signaling pathway
|
|
Estrogen signaling pathway
|
|
Oxytocin signaling pathway
|
|
Type II diabetes mellitus
|
|
Aldosterone-regulated sodium reabsorption
|
|
Prion diseases
|
|
Alcoholism
|
|
Shigellosis
|
|
Salmonella infection
|
|
Pertussis
|
|
Leishmaniasis
|
|
Chagas disease (American trypanosomiasis)
|
|
Toxoplasmosis
|
|
Tuberculosis
|
|
Hepatitis B
|
|
Viral carcinogenesis
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
Renal cell carcinoma
|
|
Pancreatic cancer
|
|
Glioma
|
|
Thyroid cancer
|
|
Melanoma
|
|
Bladder cancer
|
|
Chronic myeloid leukemia
|
|
Acute myeloid leukemia
|
|
Non-small cell lung cancer
|
|
Central carbon metabolism in cancer
|
|
Choline metabolism in cancer
|
|
NetPath Pathway
|
RANKL Signaling PathwayNetPath_7:TGF_beta_Receptor Signaling PathwayNetPath_14:IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Alzheimer disease-presenilin pathway
|
|
Angiogenesis
|
|
Cadherin signaling pathway
|
|
Hedgehog signaling pathway
|
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Insulin/IGF pathway-protein kinase B signaling cascade
|
|
Interleukin signaling pathway
|
|
PDGF signaling pathway
|
|
PI3 kinase pathway
|
|
Wnt signaling pathway
|
|
Ras Pathway
|
|
CCKR signaling map STP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Ras PathwayP00003:Alzheimer disease-amyloid secretase pathway
|
|
Apoptosis signaling pathway
|
|
B cell activation
|
|
EGF receptor signaling pathway
|
|
Endothelin signaling pathway
|
|
FGF signaling pathway
|
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade
|
|
Interferon-gamma signaling pathway
|
|
Parkinson disease
|
|
TGF-beta signaling pathway
|
|
T cell activation
|
|
VEGF signaling pathway
|
|
Angiotensin II-stimulated signaling through G proteins and beta-arrestin
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
p73 transcription factor network
|
|
E2F transcription factor network
|
|
PLK1 signaling events
|
|
AP-1 transcription factor network
|
|
FOXM1 transcription factor network
|
|
Retinoic acid receptors-mediated signalinglysophospholipid_pathway:LPA receptor mediated events
|
|
Degradation of beta catenin
|
|
Reelin signaling pathway
|
|
Presenilin action in Notch and Wnt signaling
|
|
Integrin-linked kinase signaling
|
|
CDC42 signaling events
|
|
LKB1 signaling events
|
|
Canonical Wnt signaling pathway
|
|
Role of Calcineurin-dependent NFAT signaling in lymphocytes
|
|
Glucocorticoid receptor regulatory network
|
|
C-MYC pathway
|
|
Regulation of Androgen receptor activity
|
|
BMP receptor signaling
|
|
Hedgehog signaling events mediated by Gli proteins
|
|
Signaling events mediated by Stem cell factor receptor (c-Kit)
|
|
Validated transcriptional targets of deltaNp63 isoforms
|
|
Aurora A signaling
|
|
Insulin-mediated glucose transport
|
|
Class I PI3K signaling events mediated by Akt
|
|
p53 pathway
|
|
Trk receptor signaling mediated by PI3K and PLC-gammabetacatenin_deg_pathway:Degradation of beta catenin
|
|
Class I PI3K signaling events mediated by Aktfcer1pathway:Fc-epsilon receptor I signaling in mast cells
|
|
Endothelins
|
|
BCR signaling pathway
|
|
Signaling events mediated by PRL
|
|
ErbB4 signaling events
|
|
GMCSF-mediated signaling events
|
|
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
|
|
S1P3 pathway
|
|
EPHB forward signaling
|
|
Osteopontin-mediated events
|
|
S1P4 pathway
|
|
TRAIL signaling pathway
|
|
Signaling events regulated by Ret tyrosine kinase
|
|
Angiopoietin receptor Tie2-mediated signaling
|
|
S1P1 pathway
|
|
Regulation of Telomerase
|
|
Netrin-mediated signaling events
|
|
Arf6 downstream pathway
|
|
mTOR signaling pathway
|
|
Class IB PI3K non-lipid kinase events
|
|
IL2-mediated signaling events
|
|
EGF receptor (ErbB1) signaling pathway
|
|
Ras signaling in the CD4+ TCR pathway
|
|
Ceramide signaling pathway
|
|
Integrins in angiogenesis
|
|
IFN-gamma pathway
|
|
ErbB1 downstream signaling
|
|
ATF-2 transcription factor network
|
|
ErbB2/ErbB3 signaling events
|
|
ALK1 signaling events
|
|
PDGFR-beta signaling pathway
|
|
Neurotrophic factor-mediated Trk receptor signaling
|
|
Syndecan-1-mediated signaling events
|
|
Retinoic acid receptors-mediated signaling
|
|
Nongenotropic Androgen signaling
|
|
CXCR3-mediated signaling events
|
|
VEGFR1 specific signals
|
|
Regulation of cytoplasmic and nuclear SMAD2/3 signaling
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
Syndecan-2-mediated signaling events
|
|
Cellular roles of Anthrax toxin
|
|
S1P2 pathway
|
|
Trk receptor signaling mediated by the MAPK pathway
|
|
Downstream signaling in naï
|
|
VEGFR3 signaling in lymphatic endothelium
|
|
Alpha-synuclein signaling
|
|
FGF signaling pathway
|
|
Signaling events mediated by focal adhesion kinase
|
|
PathWhiz Pathway
|
Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
|
|
Intracellular Signalling Through Adenosine Receptor A2b and Adenosine
|
|
Fc Epsilon Receptor I Signaling in Mast Cells
|
|
Insulin Signalling
|
|
Reactome
|
MAPK3 (ERK1) activation
|
|
E2F mediated regulation of DNA replication
|
|
G0 and Early G1
|
|
Cyclin B2 mediated events
|
|
Golgi Cisternae Pericentriolar Stack Reorganization
|
|
Cdc20:Phospho-APC/C mediated degradation of Cyclin A
|
|
Regulation of APC/C activators between G1/S and early anaphase
|
|
Phosphorylation of the APC/C
|
|
Phosphorylation of Emi1
|
|
Condensation of Prophase Chromosomes
|
|
MASTL Facilitates Mitotic Progression
|
|
Resolution of Sister Chromatid Cohesion
|
|
Condensation of Prometaphase Chromosomes
|
|
Regulation of PLK1 Activity at G2/M Transition
|
|
Activation of NIMA Kinases NEK9, NEK6, NEK7
|
|
Loss of Nlp from mitotic centrosomes
|
|
Recruitment of mitotic centrosome proteins and complexes
|
|
Loss of proteins required for interphase microtubule organization?from the centrosome
|
|
Recruitment of NuMA to mitotic centrosomes
|
|
Depolymerisation of the Nuclear Lamina
|
|
Anchoring of the basal body to the plasma membrane
|
|
MAPK6/MAPK4 signaling
|
|
G1/S-Specific Transcription
|
|
Cyclin A/B1 associated events during G2/M transition
|
|
G2/M DNA replication checkpoint
|
|
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complexR-HSA-195253:Degradation of beta-catenin by the destruction complex
|
|
AKT phosphorylates targets in the cytosol
|
|
Regulation of HSF1-mediated heat shock response
|
|
CRMPs in Sema3A signaling
|
|
Disassembly of the destruction complex and recruitment of AXIN to the membrane
|
|
S33 mutants of beta-catenin aren't phosphorylated
|
|
S37 mutants of beta-catenin aren't phosphorylated
|
|
S45 mutants of beta-catenin aren't phosphorylated
|
|
T41 mutants of beta-catenin aren't phosphorylated
|
|
Degradation of GLI2 by the proteasome
|
|
Constitutive Signaling by AKT1 E17K in CancerR-HSA-198323:AKT phosphorylates targets in the cytosol
|
|
XBP1(S) activates chaperone genes
|
|
Constitutive Signaling by AKT1 E17K in CancerR-HSA-112409:RAF-independent MAPK1/3 activation
|
|
MAPK1 (ERK2) activation
|
|
ERK/MAPK targets
|
|
Regulation of actin dynamics for phagocytic cup formation
|
|
Oxidative Stress Induced Senescence
|
|
Senescence-Associated Secretory Phenotype (SASP)
|
|
Oncogene Induced Senescence
|
|
FCERI mediated MAPK activation
|
|
NCAM signaling for neurite out-growth
|
|
Recycling pathway of L1
|
|
CREB phosphorylation through the activation of Ras
|
|
Activation of the AP-1 family of transcription factors
|
|
Thrombin signalling through proteinase activated receptors (PARs)
|
|
Negative regulation of FGFR1 signaling
|
|
Negative regulation of FGFR2 signaling
|
|
Negative regulation of FGFR3 signaling
|
|
Negative regulation of FGFR4 signaling
|
|
RHO GTPases Activate WASPs and WAVEs
|
|
RAF/MAP kinase cascade
|
|
MAP2K and MAPK activation
|
|
Negative feedback regulation of MAPK pathway
|
|
Negative regulation of MAPK pathway
|
|
Signal attenuation
|
|
Advanced glycosylation endproduct receptor signaling
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
Growth hormone receptor signaling
|
|
WikiPathways
|
DNA Damage Response
|
|
G1 to S cell cycle control
|
|
TGF beta Signaling Pathway
|
|
PPAR Alpha Pathway
|
|
MAP kinase activation in TLR cascade
|
|
RAF/MAP kinase cascade
|
|
Mitotic Prophase
|
|
Mitotic Prometaphase
|
|
BMI1
|
|
ATM Signaling Pathway
|
|
Retinoblastoma (RB) in Cancer
|
|
Spinal Cord Injury
|
|
Prostate Cancer
|
|
Regulation of Microtubule Cytoskeleton
|
|
Integrated Cancer pathway
|
|
Mitotic G2-G2/M phases
|
|
Mitotic G1-G1/S phases
|
|
Cell Cycle
|
|
APC/C-mediated degradation of cell cycle proteins
|
|
Cell Cycle Checkpoints
|
|
miRNA Regulation of DNA Damage ResponseWP710:DNA Damage Response (only ATM dependent)
|
|
Senescence and Autophagy in Cancer
|
|
Notch Signaling Pathway
|
|
Glycogen Metabolism
|
|
Insulin Signaling
|
|
Wnt Signaling Pathway
|
|
Wnt Signaling Pathway and Pluripotency
|
|
IL-6 signaling pathway
|
|
Wnt Signaling Pathway Netpath
|
|
Copper homeostasis
|
|
Focal Adhesion
|
|
Hair Follicle Development: Induction (Part 1 of 3)
|
|
Cardiac Hypertrophic Response
|
|
Degradation of beta-catenin by the destruction complex
|
|
T-Cell Receptor and Co-stimulatory Signaling
|
|
Cardiac Progenitor Differentiation
|
|
BDNF signaling pathway
|
|
Corticotropin-releasing hormone
|
|
B Cell Receptor Signaling Pathway
|
|
IL17 signaling pathway
|
|
Neural Crest Differentiation
|
|
Alzheimers Disease
|
|
IL-7 Signaling Pathway
|
|
TWEAK Signaling Pathway
|
|
Leptin signaling pathway
|
|
Semaphorin interactions
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
|
Androgen receptor signaling pathway
|
|
IL-5 Signaling PathwayWP500:Glycogen Metabolism
|
|
Activation of Chaperone Genes by XBP1(S)
|
|
Integrated Pancreatic Cancer Pathway
|
|
Integrated Breast Cancer Pathway
|
|
SREBP signalling
|
|
IL-5 Signaling PathwayWP75:Toll-like receptor signaling pathway
|
|
Serotonin Receptor 4/6/7 and NR3C Signaling
|
|
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
|
|
Serotonin HTR1 Group and FOS Pathway
|
|
Vitamin A and Carotenoid Metabolism
|
|
DNA Damage Response (only ATM dependent)
|
|
TCR Signaling Pathway
|
|
ErbB Signaling Pathway
|
|
Hypothetical Network for Drug Addiction
|
|
EPO Receptor Signaling
|
|
Regulation of Actin Cytoskeleton
|
|
IL-2 Signaling Pathway
|
|
EGF/EGFR Signaling Pathway
|
|
MAPK Cascade
|
|
IL-4 Signaling Pathway
|
|
MAPK Signaling Pathway
|
|
Signaling of Hepatocyte Growth Factor Receptor
|
|
Kit receptor signaling pathway
|
|
TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer
|
|
Apoptosis-related network due to altered Notch3 in ovarian cancer
|
|
IL-3 Signaling Pathway
|
|
Bladder Cancer
|
|
Fc epsilon receptor (FCERI) signaling
|
|
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
|
|
Nanoparticle-mediated activation of receptor signaling
|
|
Structural Pathway of Interleukin 1 (IL-1)
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
|
EBV LMP1 signaling
|
|
Signal Transduction of S1P Receptor
|
|
Nifedipine Activity
|
|
Aryl Hydrocarbon Receptor
|
|
PDGF Pathway
|
|
Alpha 6 Beta 4 signaling pathway
|
|
Oncostatin M Signaling Pathway
|
|
Interleukin-11 Signaling Pathway
|
|
AGE/RAGE pathway
|
|
TNF alpha Signaling Pathway
|
|
Signaling Pathways in Glioblastoma
|
|
TSLP Signaling Pathway
|
|
IL-9 Signaling Pathway
|
|
Endothelin Pathways
|
|
FSH signaling pathway
|
|
RANKL/RANK Signaling Pathway
|
|
Opioid Signalling
|
|
IL-1 signaling pathway
|
|
Thrombin signalling through proteinase activated receptors (PARs)
|
|
Signaling by FGFR
|
|
Integrin-mediated Cell Adhesion
|
|
L1CAM interactions
|
|
Advanced glycosylation endproduct receptor signaling
|
|
Heart Development
|
|
Type II diabetes mellitus
|
|
Angiogenesis
|
|
Physiological and Pathological Hypertrophy of the Heart
|
|
Regulation of toll-like receptor signaling pathway
|
|
Osteopontin Signaling
|
|
IL-5 Signaling Pathway
|
| References |
| REF 1 | Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice. Diabetes. 1999 Aug;48(8):1662-6. |
|---|
| REF 2 | Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95. |
|---|
